Although a randomized study reported a lower OHSS incidence and lower cycle cancellation rate in the r-LH supplementation group that was downregulated by GnRH agonists [21], no significant differences were observed in the present study. The gene discussed is PLOD1; the disease is ovarian hyperstimulation syndrome.